ACE2 and COVID-19: SARS-CoV-2 hijacks cellular ACE2 and disrupts these protective effects, which could explain the increased prevalence and severity of COVID-19 in patients with hypertension, diabetes, and metabolic diseases who already suffer from increased Ang-II/AT1R signaling and/or reduced ACE2 function68.